Table 2 Observation indexes between the treatment group and control group 6–12 months after HSCT.

From: Analysis of the benefit of gonadotropin-releasing hormone agonist treatment in premenopausal women undergoing hematopoietic cell transplantation

 

Treatment group, n = 77(%)

Control group, n = 157(%)

P value

Vaginal bleeding in LAFR

19 (24.68)

125 (79.62)

< 0.001

Symptoms

 Hot flushes

32 (41.56)

74 (47.13)

0.421

 Sweating

24 (31.17)

64 (40.76)

0.155

 Nervousness

30 (38.96)

35 (22.29)

0.007

 Insomnia

21 (27.27)

74 (47.13)

0.004

 Sexual problems

10 (12.99)

40 (25.78)

0.029

 None

36 (46.75)

31 (19.75)

< 0.001

Follicles visible on gynecological ultrasound

13 (16.88)

21 (13.38)

0.474

FSH (mIU/ml)

98.00

117.53

0.001

LH (mIU/ml)

65.07

61.38

0.127

FSH < 40 mIU/ml

5 (6.49)

4 (2.55)

0.266

Recovering menstrual Cycles

1 (1.30)

0 (0)

0.329

  1. P value indicates the differences between the two groups.
  2. LAFR laminar air-flow room, HSCT hematopoietic stem cell transplantation, GnRHa gonadotropin-releasing hormone agonist, FSH follicle-stimulating hormone, LH luteinizing hormone.
Back to article page